Vaccine Info

COVID-19 Vaccines

Authored by
Staff
Last reviewed
August 5, 2022
Share

COVID-19 Vaccines In 2022

The U.S. Food and Drug Administration (FDA) has Approved two COVID-19 vaccines and issued three Emergency Use Authorizations. The initial FDA Approval was for the Pfizer-BioNTech Comirnaty vaccine on August 23, 2021, followed by Moderna's SpikeVax vaccine on February 4, 2022.

And the FDA Authorized the Jcovden COVID-19 vaccine from Janssen - Johnson & Johnson on February 27, 2021, then on July 13, 2022, the FDA Authorized the Novavax COVID-19 Vaccine (Nuvaxovid™).

COVID-19 vaccine availability and vaccination schedules were recently updated.

The U.S. CDC reported on August 3, 2022, that about 67.2% of the U.S. population had been 'fully vaccinated' with an Approve/Authorized COVID-19 vaccine, and about 48.2% of eligible people have been 'boosted' with a third vaccination, and 30.1% of the 5-11-year-old group have been fully vaccinated. As of July, approximately 544,000 children under the age of five had received at least one COVID-19 vaccine dose, representing about 2.8% of children in this age group. 

On July 19, 2022, Katherine E. Fleming-Dutra, M.D., COVID-19 Epidemiology Task Force, presented to the CDC's Advisory Committee on Immunization Practices: COVID-19 Epidemiology and Vaccination Rates in the USA.

Separately, the European Centre for Disease Prevention and Control reported on July 21, 2022, that about 73% of adult Europeans had completed their primary vaccination course, while about 5.1% have been fully 'boosted' with a fourth dose.

In Europe, the European Medicines Agency authorized six COVID-19 vaccines and is reviewing four other vaccines, and reports side effect data monthly. The WHO's COVID-19 vaccine tracker compiles detailed information about (166) COVID-19 vaccine candidates in development.

COVID-19 Vaccine Booster Authorizations For 2022

The WHO says 'booster doses should be considered for all COVID-19 vaccines.' The U.S. FDA authorized a second booster dose (4th vaccination) for older people and certain immunocompromised individuals on March 29, 2022. 

COVID-19 Vaccine Effectiveness Against SARS-CoV-2 Virus Variants (Omicron and BA.x sublineages) 

As of July 21, 2022, the U.S. NIH OpenData Portal presents a database of COVID-19 vaccine in vitro therapeutic activity against SARS-CoV-2 Omicron sublineages. And the CDC's NowCast monitors active variants on a local level in the U.S. Separately, the U.K's CoVariants provide an overview of SARS-CoV-2 variants and mutations, as does the WHO.

COVID-19 Vaccinations For Infants, Toddlers, and Adolescents

The U.S. CDC and FDA have authorized mRNA COVID-19 vaccines for 6-month-old and older children.

Monoclonal Antibody Treatments and COVID-19 Antivirals

Various anti-SARS-CoV-2 mAbs and COVID-19 antivirals (oral and IV) are U.S. FDA Authorized.

NOTES:

  • As of July 7, 2022, more than 258 million COVID-19 vaccine doses had been reported by Federal Retail Pharmacy Program with 41,000 participants, including long-term care pharmacies.

  • The CDC recently clarified that 'COVID-19 vaccines and other vaccines may be coadministered on the same day.

  • The Vaccine Adverse Event Reporting System (VAERS) is a passive reporting system, meaning it relies on individuals to send in reports of their experiences. Anyone can submit a vaccine side effect report to VAERS, including parents and patients.
  • Search vaccines.gov, text your zip code to 438829, or call 1-800-232-0233 to find COVID-19 vaccine locations near you in the USA.
  • Vaccine and medication discount information are published by InstantRx.com.

Clinical Trials

No clinical trials found